These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 35337940)

  • 1. Delivery of mRNA for regulating functions of immune cells.
    Shi J; Huang MW; Lu ZD; Du XJ; Shen S; Xu CF; Wang J
    J Control Release; 2022 May; 345():494-511. PubMed ID: 35337940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-liver mRNA Delivery.
    Loughrey D; Dahlman JE
    Acc Chem Res; 2022 Jan; 55(1):13-23. PubMed ID: 34859663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
    Wang C; Zhang Y; Dong Y
    Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery.
    Long J; Yu C; Zhang H; Cao Y; Sang Y; Lu H; Zhang Z; Wang X; Wang H; Song G; Yang J; Wang S
    Adv Healthc Mater; 2023 May; 12(13):e2202590. PubMed ID: 36716702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery Strategies for mRNA Vaccines.
    Ramachandran S; Satapathy SR; Dutta T
    Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-printed microfluidic device for high-throughput production of lipid nanoparticles incorporating SARS-CoV-2 spike protein mRNA.
    Lin WS; Bostic WKV; Malmstadt N
    Lab Chip; 2024 Jan; 24(2):162-170. PubMed ID: 38165143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA delivery technologies: Toward clinical translation.
    Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
    Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery.
    Sun M; Dang UJ; Yuan Y; Psaras AM; Osipitan O; Brooks TA; Lu F; Di Pasqua AJ
    AAPS PharmSciTech; 2022 May; 23(5):135. PubMed ID: 35534697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
    Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of
    Jung HN; Lee SY; Lee S; Youn H; Im HJ
    Theranostics; 2022; 12(17):7509-7531. PubMed ID: 36438494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].
    Jawalagatti V; Kirthika P; Lee JH
    Front Immunol; 2022; 13():884862. PubMed ID: 35592330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid nanoparticles in the development of mRNA vaccines for COVID-19.
    Wilson B; Geetha KM
    J Drug Deliv Sci Technol; 2022 Aug; 74():103553. PubMed ID: 35783677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates.
    Ripoll M; Bernard MC; Vaure C; Bazin E; Commandeur S; Perkov V; Lemdani K; Nicolaï MC; Bonifassi P; Kichler A; Frisch B; Haensler J
    Biomaterials; 2022 Jul; 286():121570. PubMed ID: 35576809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery
    Hadjiargyrou M
    Nucleic Acid Ther; 2021 Oct; 31(5):321-323. PubMed ID: 33960839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.